BMO Capital Starts Radient Pharmaceuticals (RPC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RPC Hot Sheet
Price: $9.88 +5.11%
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
BMO Capital initiates coverage on Radient Pharmaceuticals (NYSE: RPC) with a Outperform rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Radient Pharmaceuticals click here. For more ratings news on Radient Pharmaceuticals click here.
Shares of Radient Pharmaceuticals closed at $0.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Goldman Sachs Assumes Skyworks Solutions (SWKS) at Sell
- Citi Starts TCL Electronics Holdings (1070:HK) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
